NAS:IART (USA) Also trade in: Germany

Integra Lifesciences Holdings Corp

$ 59.9 0 (-2.63%)
Volume: 328,834 Avg Vol (1m): 449,977
Market Cap $: 5.12 Bil Enterprise Value $: 6.41 Bil
P/E (TTM): 51.64 P/B: 3.59
Earnings Power Value -13.21
Net Current Asset Value -11.75
Tangible Book -6.43
Projected FCF 22.88
Median P/S Value 30.94
Graham Number 0
Peter Lynch Value 10.01
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.12
Cash-To-Debt range over the past 10 years
Min: 0.07, Med: 0.34, Max: 10000
Current: 0.12
0.07
10000
Equity-to-Asset 0.43
Equity-to-Asset range over the past 10 years
Min: 0.29, Med: 0.49, Max: 0.97
Current: 0.43
0.29
0.97
Debt-to-Equity 1.03
Debt-to-Equity range over the past 10 years
Min: 0.02, Med: 0.89, Max: 2.01
Current: 1.03
0.02
2.01
Debt-to-EBITDA 5.56
Debt-to-EBITDA range over the past 10 years
Min: 2.83, Med: 5, Max: 13.6
Current: 5.56
2.83
13.6
Interest Coverage 2.48
Interest Coverage range over the past 10 years
Min: 1.28, Med: 3.21, Max: 5.38
Current: 2.48
1.28
5.38
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.63
DISTRESS
GREY
SAFE
Beneish M-Score -2.49
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 5.41%
WACC 10.72%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 9.12
Operating Margin range over the past 10 years
Min: 3.77, Med: 8.7, Max: 14.33
Current: 9.12
3.77
14.33
Net Margin % 6.76
Net Margin range over the past 10 years
Min: -3.02, Med: 4.62, Max: 8.97
Current: 6.76
-3.02
8.97
ROE % 7.31
ROE range over the past 10 years
Min: -3.56, Med: 6.42, Max: 13.9
Current: 7.31
-3.56
13.9
ROA % 3.16
ROA range over the past 10 years
Min: -1.79, Med: 2.59, Max: 6.71
Current: 3.16
-1.79
6.71
ROC (Joel Greenblatt) % 21.03
ROC (Joel Greenblatt) range over the past 10 years
Min: 8.29, Med: 17.62, Max: 32.36
Current: 21.03
8.29
32.36
3-Year Total Revenue Growth Rate 18.60
3-Year Revenue Growth Rate range over the past 10 years
Min: -5.3, Med: 14.8, Max: 55
Current: 12.3
-5.3
55
3-Year Total EBITDA Growth Rate 17.60
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 8.8, Max: 39.7
Current: 11.4
0
39.7
3-Year EPS w/o NRI Growth Rate 93.10
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 4.1, Max: 93.1
Current: 93.1
0
93.1

Ratios

Current vs industry vs history
PE Ratio (TTM) 51.64
PE Ratio range over the past 10 years
Min: 15.26, Med: 43.86, Max: 6446
Current: 51.64
15.26
6446
Forward PE Ratio 21.93
N/A
PE Ratio without NRI 51.64
PE without NRI range over the past 10 years
Min: 15.26, Med: 41.54, Max: 506.24
Current: 51.64
15.26
506.24
Price-to-Owner-Earnings 43.88
Price-to-Owner-Earnings range over the past 10 years
Min: 8.25, Med: 38.49, Max: 1344.69
Current: 43.88
8.25
1344.69
PB Ratio 3.59
PB Ratio range over the past 10 years
Min: 1.24, Med: 2.37, Max: 5.09
Current: 3.59
1.24
5.09
PS Ratio 3.47
PS Ratio range over the past 10 years
Min: 0.79, Med: 1.79, Max: 4.19
Current: 3.47
0.79
4.19
Price-to-Free-Cash-Flow 41.77
Price-to-Free-Cash-Flow range over the past 10 years
Min: 6.16, Med: 30.04, Max: 122.19
Current: 41.77
6.16
122.19
Price-to-Operating-Cash-Flow 25.86
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 5.38, Med: 19.7, Max: 40.49
Current: 25.86
5.38
40.49
EV-to-EBIT 42.24
EV-to-EBIT range over the past 10 years
Min: -149.8, Med: 30.7, Max: 128.6
Current: 42.24
-149.8
128.6
EV-to-EBITDA 24.42
EV-to-EBITDA range over the past 10 years
Min: 8.1, Med: 19.3, Max: 44.1
Current: 24.42
8.1
44.1
EV-to-Revenue 4.29
EV-to-Revenue range over the past 10 years
Min: 1.3, Med: 2.5, Max: 5.3
Current: 4.29
1.3
5.3
PEG Ratio 3.94
PEG Ratio range over the past 10 years
Min: 0.56, Med: 3.84, Max: 2812.44
Current: 3.94
0.56
2812.44
Shiller PE Ratio 90.19
Shiller PE Ratio range over the past 10 years
Min: 17.3, Med: 38.87, Max: 115.91
Current: 90.19
17.3
115.91
Current Ratio 2.76
Current Ratio range over the past 10 years
Min: 0.81, Med: 4.2, Max: 20.74
Current: 2.76
0.81
20.74
Quick Ratio 1.82
Quick Ratio range over the past 10 years
Min: 0.46, Med: 2.61, Max: 19.26
Current: 1.82
0.46
19.26
Days Inventory 187.62
Days Inventory range over the past 10 years
Min: 184.16, Med: 214.3, Max: 247.25
Current: 187.62
184.16
247.25
Days Sales Outstanding 72.51
Days Sales Outstanding range over the past 10 years
Min: 50.48, Med: 54.95, Max: 77.35
Current: 72.51
50.48
77.35
Days Payable 69.58
Days Payable range over the past 10 years
Min: 30.38, Med: 38.34, Max: 78.75
Current: 69.58
30.38
78.75

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -8.70
3-Year Share Buyback Rate range over the past 10 years
Min: -19.5, Med: -3.5, Max: 2.9
Current: -8.7
-19.5
2.9

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 2.62
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.62, Med: 1.85, Max: 9.6
Current: 2.62
0.62
9.6
Price-to-Median-PS-Value 1.94
Price-to-Median-PS-Value range over the past 10 years
Min: 0.54, Med: 1.81, Max: 10.73
Current: 1.94
0.54
10.73
Price-to-Peter-Lynch-Fair-Value 5.98
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.35, Med: 1.38, Max: 9.47
Current: 5.98
0.35
9.47
Earnings Yield (Joel Greenblatt) % 2.37
Earnings Yield (Greenblatt) range over the past 10 years
Min: -0.8, Med: 3.1, Max: 8.6
Current: 2.37
-0.8
8.6
Forward Rate of Return (Yacktman) % 10.35
Forward Rate of Return range over the past 10 years
Min: -8.8, Med: 12.2, Max: 28.5
Current: 10.35
-8.8
28.5

» IART's 30-Y Financials

Financials (Next Earnings Date: 2019-10-31)

» Interactive Chart

Peter Lynch Chart

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:IART

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339112    SIC : 3841
Compare NYSE:GMED NYSE:PEN OCSE:GN HKSE:01066 SZSE:300529 NAS:TNDM SZSE:300003 NAS:LIVN OCSE:AMBU B NAS:NUVA SZSE:002223 NAS:LVGO XSWX:TECN OCSE:OSSR NAS:CNMD NAS:WMGI NYSE:NVRO TSE:6849 NYSE:ITGR SHSE:688029
Traded in other countries IL3.Germany
Address 311 Enterprise Drive, Plainsboro, NJ, USA, 08536
Integra Lifesciences Holdings Corp is a medical technology company that provides regenerative, specialty surgical, and orthopedic solutions to surgeons. The firm operates in two segments: specialty surgical solutions, and orthopedics and tissue technology. The specialty surgical solutions business contributes the majority of revenue. It sells surgical instruments for a variety of specialties, including products for dural repair, precision instruments, tissue ablation, and neuro-critical care. The orthopedics and tissue technology business sells soft-tissue repair and tissue-regeneration products and small-bone fixation and joint-replacement solutions. Integra generates the majority of its revenue in the United States.

More Statistics

Revenue (TTM) (Mil) $ 1,492.5
EPS (TTM) $ 1.16
Beta 1.38
Volatility % 43.73
52-Week Range $ 42.14 - 66.41
Shares Outstanding (Mil) 85.53

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N